Leerink Partners analyst Marc Goodman has maintained their bullish stance on MNMD stock, giving a Buy rating yesterday.Invest with Confidence: ...

NeuroStar is committed to advancing the body of scientific research and elevating mental health treatment through robust research and data-driven innovation,” stated Keith J. Sullivan, President and ...

Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is difficult to treat. The United States Food and Drug Administration (FDA ...

Drug is the first and only approved monotherapy for refractory major depressive disorder. (HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of MDD in those who have not responded to at least two oral antidepressants. Hundreds of ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

However, it may cover Spravato, an FDA-approved drug deriving from ketamine, for treatment-resistant depression. Currently, the Food and Drug Administration (FDA) only approves ketamine for use as ...

Spravato has been approved since 2019 for TRD, with its label extended the following year as a rescue therapy for adults with major depressive disorder (MDD) who were at risk of self-harm or suicide.